Hartgers ML, et al. - The impact of double heterozygous, compound heterozygous, or homozygous mutations underlying familial hypercholesterolemia (FH) on the efficacy of alirocumab was comprehensively examined during this research. Data disclosed clinically significant low-density lipoprotein cholesterol (LDL-C)-lowering activity in patients receiving alirocumab who were double heterozygous, compound heterozygous, or homozygous for genes which were causative for FH.